Contributors

Molly Billstein Leber, PharmD, BCPS, FASHP, is manager, Medication Policy and Formulary Management, Yale New Haven System in New Haven, Connecticut. She received her PharmD degree from the University of Montana and completed a PGY1 Residency at Yale New Haven Hospital. Leber’s career focuses on formulary standardization, drug use policy, pharmacy informatics, and promoting safe and efficient use of medications.
John Bujnoski is Managing Director of Pangea Advisory and Consulting, LLC, a strategic marketing consulting firm focused on the specialty biopharmaceutical and biosimilar market segments. John has extensive global biopharmaceutical industry expertise including extensive knowledge and understanding of the global market environment including pricing, market access, and reimbursement systems.
Kashyap Patel, MD, is the managing partner at Carolina Blood and Cancer Care and has been with them since its inception in 2004. Dr Patel received his medical degree from Thomas Jefferson University Hospital, has authored several research articles regarding melanoma, and is board certified in hematology, oncology, and internal medicine.
Stacie Phan, MBA, MS, is president of the Biosimilars Forum. Ms. Phan has more than 20 years of experience in pharmaceutical research, government affairs, public policy analysis, and business operations. Currently she is Director of State Government Affairs and Public Policy, serving as Boehringer Ingelheim’s state government relations lead and key strategist for researching and developing company positions on public policy issues in the United States. Previously, Ms. Phan worked at Bayer HealthCare in public policy including reimbursement policy, oncology, and hemophilia.
Robert Levin, MD, is a practicing rheumatologist and patient advocate. He serves as president of the Florida Society of Rheumatology and chair of the Alliance for Transparent and Affordable Prescriptions (ATAP), a coalition of healthcare provider and patient groups concerned about the practices of pharmacy benefit managers (PBMs).
Amanda Forys, MSPH, is a senior director at Xcenda, a part of AmerisourceBergen, on the Reimbursement Strategy Insights consulting team. Her experience includes reimbursement policy analytics, with emphases on Medicare and commercial coverage and payment policy. Her work has covered a wide range of topics, including economic and policy modeling and analysis around biosimilars, innovative payment models, chronic disease management, federal budgetary impact models, and Medicare payment systems. 
Steven Lucio, PharmD, BCPS, is associate vice president for the Center for Pharmacy Practice Excellence at Vizient, a health care supply chain and analytics company in Irving, Texas. During his tenure, he has had responsibility for providing clinical education to member organizations on practice topics including improving medication safety, mitigating the impact of drug shortages, benchmarking pharmacy costs for key drug classes, evaluating the expense of high-cost biologics and specialty drugs, and preparing for future trends such as the development of biosimilars. Prior to joining Vizient, Steven practiced for almost 10 years within the Baylor Health Care System in both inpatient and ambulatory care.
Sonia T. Oskouei, PharmD, is the Director of Pharmacy Program Development for Biosimilars at Premier Inc. Within the provider-led organization, she has the unique role of leading the national biosimilar strategy on behalf of nearly 3800 hospitals and health systems. Through the development of educational resources and tools, she supports health system stakeholders evaluate and manage biosimilars, and works with biosimilar manufacturers on market considerations including financial, clinical, and operational decisions. She previously oversaw pharmacy purchasing and procurement for Novant Health. 
Carlos Sattler, MD, is the head of clinical development and medical affairs at Sandoz, Inc. In this capacity, Sattler leads efforts in the United States to develop and implement Sandoz’s medical and scientific strategy, medical education and communication initiatives, and data-generation activities in support of biosimilars and other Sandoz products. Sattler specialized in pediatric medicine and is subspecialty trained in pediatric infectious diseases.
ZS is the world’s largest firm focused exclusively on helping companies improve overall performance and grow revenue and market share through end-to-end sales and marketing solutions—from customer insights and strategy, to analytics, operations and technology. More than 5,500 ZS professionals in 22 offices worldwide draw on deep industry and domain expertise to deliver impact for clients across multiple industries.
Gregory Schimizzi, MD, is a co-convener of the Biologics Prescribers Collaborative (BPC) and the cofounder of Carolina Arthritis Associates, PA, in Wilmington, NC.  He has been a licensed and board-certified rheumatologist in private practice for 30 years. He co-founded, and previously served as president, of the Coalition for State Rheumatology Organizations (CSRO). He has also previously served as president, and a member of the executive board, at the North Carolina Rheumatology Association. Dr Schimizzi completed his undergraduate and medical school studies at Wayne State University in Detroit and completed his fellowship training at the University of California at Irvine.
Corey Greenblatt, MPH, is the manager of policy and advocacy of CreakyJoints and The Global Healthy Living Foundation. The Global Healthy Living Foundation is a 501(c)(3) non-profit organization whose mission is to improve the quality of life for people living with chronic illnesses (such as arthritis, osteoporosis, migraine, diabetes, psoriasis, and cardiovascular disease) by advocating for improved access to health care at the community, state, and federal levels, and amplifying education and awareness efforts within its social media framework. The Global Healthy Living Foundation is the parent organization of CreakyJoints, the digital community and advocacy organization for millions of arthritis patients and caregivers worldwide who seek education, support, advocacy, and patient-centered research through ArthritisPower, the first-ever patient-centered research registry for joint, bone, and inflammatory skin conditions. Visit www.GHLF.org for more information.
Rick Lozano is the Vice President of Biosimilars and Integrated Business Development for AmerisourceBergen. His responsibilities span across AmerisourceBergen, working with internal teams and manufacturer partners to create and manage innovative biosimilar and follow-on biologic manufacturer relationships. In addition to his leadership in biosimilars, Lozano leads the team connecting AmerisourceBergen’s manufacturer sourcing and commercialization capabilities across all types of products to expand existing manufacturer partnerships and forge new business development opportunities.
David T. Rubin, MD, AGAF, is a professor of medicine and section chief of gastroenterology, hepatology, and nutrition at University of Chicago Medicine. He is a fellow of the American Gastroenterological Association (AGA), which represents over 16,000 gastroenterologists worldwide and is dedicated to empowering clinicians and researchers to improve digestive health. He is also chair-elect of the National Scientific Advisory Committee of the Crohn’s and Colitis Foundation, whose mission is to cure Crohn disease and ulcerative colitis, and to improve the quality of life of children and adults affected by these diseases. AGA is a member of the Biologics Prescribers Collaborative (BPC), an organization comprising medical societies whose members regularly prescribe biologic medicines. BPC strives to ensure that sound policies are in place to promote the safest possible development and use of all biologics, including biosimilars, for all patients.
George C. Yu, JD, is a partner in the Intellectual Property group of Schiff Hardin LLP. He is an experienced patent attorney who focuses his practice focuses on patent infringement litigation and counseling and has worked in private practice and in-house positions. George has litigated patents relating to recombinant proteins, monoclonal antibodies, microarray technology, and small molecule therapeutics. George has advised companies developing novel biologics as well as biosimilars on patent strategy.
  Christopher Bruno, JD, is an associate in the Intellectual Property group at Schiff Hardin LLP, and a former law clerk of the United States Court of Appeals for the Federal Circuit and of the United States District Court for the Central District of California. With a focus on pharmaceutical product patent litigation, he has litigated Hatch-Waxman cases from pre-complaint investigation through appeal in district courts, the Federal Circuit, the Supreme Court, and the International Trade Commission. Chris was one of the first attorneys with experience litigating the meaning of provisions of the Biologics Price Competition and Innovation Act of 2009, and continues to play a role in decoding the relatively nascent territory of biosimilar litigation.
Chad Landmon, JD, is a partner at Axinn, where he chairs the firm’s FDA and intellectual property practice groups. He regularly works with companies developing drugs, biologics, and regenerative medicine and human tissue products. Jonathan Knowles, JD, is an associate at Axinn. At this time, his admission to the New York bar is pending.
Christine Simmon is the executive director of the Biosimilars Council and senior vice president of policy and strategic alliances at the Association for Accessible Medicines (AAM). Christine leads policy development and issues management for AAM and has led the Biosimilars Council since its founding in 2015.
Ed Schoonveld is a managing principal at ZS Associates and is the leader of the firm’s value and access practice. In this role, he provides strategic consulting and research solutions to healthcare industry clients. He is considered one of the world’s leading experts on global pharmaceutical pricing and market access, and has unparalleled experience as head of global market access and pricing functions. He is the author of the book The Price of Global Health, which looks at global pharmaceutical pricing and market access.

Mauricio Rubio is a pharmacist with advanced studies in administration, and he is currently a master of business administration candidate. He has 13 years of experience in sales, marketing, and business development in Latin America for pharmaceutical and consultancy companies. He has participated as a speaker in the Jack Leckerman Biosimilars Forum in 2018 and 2019.
Sarfaraz K. Niazi, PhD, is an adjunct professor of biopharmaceutical sciences at the University of Illinois and the University of Houston, and founder of biosimilars companies Karyo Biologics and Adello Biologics. He also founded the biosimilar advisory company PharmSci.
Angus Worthing, MD, FACR, FACP, is a practicing rheumatologist at Arthritis & Rheumatism Associates in Washington, DC, and vice president of the Alliance for Transparent and Affordable Prescriptions, a coalition of patient and provider organizations working to lower prescription costs and make treatment more accessible.
 
Chad Pettit, MBA, is the executive director of global value access and policy for Amgen’s Biosimilars Business Unit. He develops global market access launch strategy for Amgen’s portfolio of 10 biosimilar medicines and leads on biosimilar policy matters in a new and rapidly growing segment of the industry. With his global perspective, Pettit is recognized as an expert on biosimilar commercialization and market access for biosimilars and the policy measures required to facilitate cost savings to patients and the healthcare system.
Hillel P. Cohen, PhD, is executive director of scientific affairs at Sandoz, helping to explain the principles of biosimilars and biosimilar policies to the healthcare community, patient advocacy groups, and health authorities. He has published and given presentations in the areas of biosimilar education, switching, interchangeability, naming, and safety. Cohen led Sandoz in its efforts on the first biosimilar presentation (Zarxio) to an FDA advisory committee and participated in the Biosimilar User Fee Amendments of 2017 negotiations on behalf of industry. He is active in biosimilar trade associations and helped cofound the Biosimilars Forum, where he is currently cochair of the education committee. He is also a member of the education and regulatory committees of the Biosimilars Council, a division of the Association for Accessible Medicines.
Madelaine Feldman, MD, is a rheumatologist in private practice with The Rheumatology Group in New Orleans, Louisiana. She is president of the Coalition of State Rheumatology Organizations, which is a founding member of the Alliance for Transparent and Affordable Prescriptions. She is also chair of the Alliance for Safe Biologic Medicines and a past member of the American College of Rheumatology’s insurance subcommittee.
Jim Hassard is a senior vice president at Coherus BioSciences. An experienced biopharmaceutical marketing executive, he has served in senior roles with Schering-Plough Canada, Amgen, and Medivation. Jim holds an MBA from Nova Southeastern University and a bachelor's degree in pharmacology from the University of Toronto.

Ron Lanton III, Esq., has over 25 years of experience in government affairs at the municipal, state, and federal government levels, with 15 years dedicated to the healthcare sector. He is a regulatory attorney and government affairs professional who frequently consults Wall Street firms on financial issues related to the healthcare sector. Lanton is a featured industry speaker on issues such as pharmaceutical safety and healthcare cost containment, and he has authored numerous articles regarding pharmacy and healthcare law. He earned a BA from Miami University and a JD from The Ohio State University. He is also the chair of the Biologics Committee for the New York Bar Association.

Isha Bangia, PharmD, MBA, is a manager of US market access at Certara Evidence & Access. She received her PharmD from Rutgers University and an MBA from Johns Hopkins University. Her current responsibilities include optimizing product value stories and working with customers to improve access across the US healthcare system. Her experience includes practicing pharmacy, payer market research, and pharma strategy and analytics. Her work has covered many therapeutic areas, including biosimilars, oncology, diabetes, vaccines, and rare diseases.
Joshua Ney, PhD, JD, is a shareholder in Brinks Gilson & Lione’s Ann Arbor office. Ney represents pharmaceutical clients in patent litigation and prosecution matters, which includes counseling clients on the interplay between regulatory and patent strategy. His experience spans a range of pharmaceutical modalities and therapeutic applications.

Click here to view Biosimilars CME Activities

Click here to view Biosimilars PTCE Activities

Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.